The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis

Journal of Rheumatology

Volumn 42, Issue 8, 2015, Pages 1448-1454

  Pinal Fernandez, Iago ^a   Casciola Rosen, Livia A ^b   Christopher Stine, Lisa ^b   Corse, Andrea M ^b   Mammen, Andrew L ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Autoimmunity; Dermatomyositis; Muscle; Myositis; Polymyositis

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; MDA5 ANTIBODY; METHOTREXATE; MI 2 ANTIBODY; NXP2 ANTIBODY; PM SCL ANTIBODY; RO52 ANTIBODY; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; BICEPS BRACHII MUSCLE; CONTROLLED STUDY; DELTOID MUSCLE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE DURATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE NECROSIS; PERIFASCICULAR ATROPHY; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RASH; VASCULITIS; BIOPSY; BLOOD; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SKELETAL MUSCLE;

ADULT; AUTOANTIBODIES; BIOPSY; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POLYMYOSITIS;

EID: 84940656454     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141443     Document Type: Article

References (18)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
2. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-45.
3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
4. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995;22:668-74.
5. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-35.
6. Varadhachary AS, Weihl CC, Pestronk A. Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol 2010;22:651-7.
7. Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol 2013;26:554-60.
8. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011;13:175-81.
9. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013;65:2954-62.
10. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60:1807-14.
11. Chaisson NF, Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine 2012;91:220-8.
12. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011;65:25-34.
13. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003;3:21.
14. Bentow C, Swart A, Wu J, Seaman A, Manfredi M, Infantino M, et al. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta 2013;424:141-7.
15. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012;24:602-8.
16. Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014;16:R138.
17. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
18. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012;41:890-9.